Business Wire
15 Nov 2026, 12:00 UTC · 1d ago
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Impact · against what's priced in
SMMT faces a significant negative catalyst as the FDA's Complete Response Letter (CRL) directly blocks the commercial launch of ivonescimab in the US. This undermines the core assumption that the regulatory process was a mere formality, shifting the timeline for revenue generation into 2027 or beyond.
- SMMT−0.80
Challenges what's priced in
- The price assumes
The FDA acceptance of the ivonescimab Biologics License Application with a November 2026 PDUFA date, treating the regulatory milestone as a known procedural step





